Eurofins Biomnis and NIPT Ninalia

NIPT is an innovative genetic screening test that detects the main foetal aneuploidies, such as Down syndrome (trisomy 21), Edwards’ syndrome (trisomy 18) and Patau syndrome (trisomy 13), in pregnant women at risk of these pathologies.

NEW

This test now also makes it possible to screen for other rarer chromosome abnormalities: autosomal abnormalities, deletions and duplications greater than 7 megabases (karyotype-equivalent resolution).

Several test options are available:

• Ninalia 3(NIPT) : Trisomies 21, 18 and 13
• Ninalia 5(NIPT) : Trisomies 21, 18 and 13 + foetal gender determination + sex chromosomes aneuploidies
• Ninalia Genomewide(NIPT): all autosomes + chromosomal imbalance greater than 7Mb Ninalia
• Genomewide Complete(NIPT): all autosomes + chromosomal imbalance greater than 7Mb + sex chromosomes aneuploidies + foetal gender determination

The non-invasive screening test uses cell-free DNA, thanks to a sampling of maternal blood. It does not carry a risk to the foetus.

The non-invasive screening test has a much greater sensitivity and specificity than serum marker screening.

Although NIPT is very sensitive and specific, it is classified as a screening option for women at increased risk of trisomies 13, 18 or 21. In cases of a positive result, an invasive diagnostic procedure, such as amniocentesis, will confirm the diagnosis.

In many cases, NIPT means that invasive sampling need not be pursued, thus reducing the associated risk of losing the foetus*.

Eurofins Biomnis follows the International recommendations of the American Congress of Obstetricians and Gynecologists (ACOG) and the Society for Maternal–Fetal Medicine (SMFM).

Geneticists who are qualified in prenatal diagnosis and responsible for Eurofins Biomnis tests are available to you as the prescriber to provide the best possible support in the implementation of this genetic test.